Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort

Table 3 Multivariate Cox regression model for prediction of MCI/AD over 2 years (N = 203).

Aβ levels	Hazard rate model A^a	P value	Hazard rate model B^b	P value	Hazard rate model C^c	P value
Aβ_1–40, pg/mL	1.00 (1.00–1.01)	0.80	1.00 (0.99–1.01)	0.51	1.00 (0.99–1.01)	0.61
Aβ_1–42 quartiles
Q1, ≤6 pg/mL	2.93 (1.02–8.32)	0.04	3.43 (1.19–9.85)	0.01	4.47 (1.39–14.39)	0.01
Q2, 6.1–12 pg/mL	1.02 (0.30–3.52)	0.98	1.11 (0.32–3.83)	0.87	0.75 (0.19–2.97)	0.68
Q3, 12.1–23 pg/mL	0.14 (0.05–2.12)	0.30	0.34 (0.63–1.80)	0.18	0.29 (0.05–1.60)	0.15
Q4, >23 pg/mL	1.00		1.00		1.00
Aβ_1–42/Aβ_1–40 ratios
Q1, ≤0.04	3.53 (1.24–10.07)	0.02	3.91 (1.36–11.24)	0.01	4.87 (1.50–15.87)	0.01
Q2, 0.05–0.08	1.36 (0.42–4.47)	0.61	1.57 (0.48–5.20)	0.46	1.39 (0.41–4.74)	0.60
Q3, 0.09–0.15	0.32 (0.04–2.77)	0.30	0.21 (0.03–1.93)	0.17	0.23 (0.03–2.14)	0.20
Q4, >0.15	1.00		1.00		1.00

^aModel A is unadjusted.
^bModel B adjusted for age, sex, and education.
^cModel C adjusted for APOE, SBP serum creatinine, triglycerides, statin use, NSAID interventions, antihypertensive use and for items in model B.
Aβ_1–40 was adjusted for Aβ_1–42 quartiles and vice versa. Q4 was used as reference category for both Aβ_1–42 and the Aβ_1–42/Aβ_1–40 ratios.

ISSN: 1528-3658